Chelsea Reinhold is providing Clinical Operations Support to PanTher Therapeutics where she is focused on clinical trial design, strategy, and execution for current and upcoming studies. Chelsea has dedicated her career on bringing novel products to market in the oncology space.
Prior to PanTher Therapeutics, Chelsea served as Senior Clinical Project Manager at Instylla where she wore many hats including managing the first IDE study for a liquid embolic indicated for tumor embolization. Before that, she led the post-market clinical department at Augmenix, acquired by Boston Scientific for $500M+. Augmenix created a hydrogel indicated to space the rectum away from the prostate for men receiving prostate cancer radiation therapy. Chelsea was also involved in researching secondary indications for hydrogel spacers including between the pancreas and duodenum for pancreatic cancer, which resulted in a completed pilot study at Massachusetts General Hospital, MD Anderson Cancer Center, and Johns Hopkins Hospital.
Chelsea holds an MS degree in Clinical Research from Massachusetts College of Pharmacy and Health Sciences and a BS in Molecular and Cellular Biology from the University of Connecticut.